Welcome to Awesome Blog Design perfect blog
Business, Healthcare

KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) demonstrated statistically significant improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) versus Sunitinib as first-line treatment for patients…

LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus Sunitinib Results of Investigational Phase 3 KEYNOTE-581/CLEAR Trial (Study 307) to be Presented at Upcoming Medical Meeting KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK): KEYTRUDA®

Business, Healthcare

Bristol Myers Squibb presents late-breaking Phase 2 data demonstrating the safety and efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis

Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases, showed significantly greater ACR 20 responses compared to placebo at 16 weeks and met all key secondary endpoints Deucravacitinib was well-tolerated with